Iaso Bio
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $74.1M
Overview
Creating engineered regulatory T-cell therapies to treat autoimmune diseases by restoring immune balance.
ImmunologyAutoimmune Diseases
Technology Platform
A platform for engineering autologous CD8+ regulatory T-cells (Tregs) with antigen-specific receptors and enhanced functional properties to restore immune tolerance in autoimmune diseases.
Funding History
1Total raised:$74.1M
PIPE$74.1M
Opportunities
Potential to achieve durable, drug-free remission in autoimmune diseases with high unmet need, leveraging the proven power of cell therapy in a new therapeutic area.
Risk Factors
Unproven safety profile of engineered Tregs in chronic autoimmune conditions and risk of over-suppression or unintended conversion to inflammatory phenotypes.
Competitive Landscape
A frontrunner in the nascent autoimmune cell therapy space, competing with other Treg-focused companies like Sangamo/Pfizer, GentiBio, and TxCell.